Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs

International Journal of Oncology

Volumn 34, Issue 5, 2009, Pages 1329-1340

  Bagley, Rebecca G ^a   Roth, Stephanie ^b   Kurtzberg, Leslie S ^a   Rouleau, Cecile ^a   Yao, Min ^a   Crawford, Jennifer ^b   Krumbholz, Roy ^b   Lovett, Dennis ^b   Schmid, Steven ^b   Teicher, Beverly A ^a  

^a GENZYME CORPORATION   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

Bone marrow CFU GM; Cladribine; Clofarabine; Fludarabine; Tumor xenografts

Indexed keywords

CLADRIBINE; CLOFARABINE; FLUDARABINE PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BONE MARROW; CANCER CELL CULTURE; CANCER INHIBITION; COLON CARCINOMA; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOMA; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; TUMOR VOLUME; TUMOR XENOGRAFT;

ADENINE NUCLEOTIDES; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOSIDES; BONE MARROW CELLS; CELLS, CULTURED; CLADRIBINE; GRANULOCYTE-MACROPHAGE PROGENITOR CELLS; HT29 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; MODELS, BIOLOGICAL; NEOPLASMS; TREATMENT OUTCOME; VIDARABINE PHOSPHATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649435470     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000260     Document Type: Article

References (47)

1. Rustum YM (ed.): Fluoropyrimidines in Cancer Therapy. Humana Press, New York, 2003.
2. Karp JR, Peters GJ and Nagourney RA: Clinical activity of gemcitabine as a single agent and in combination. In: Deoxynucleoside Analogs in Cancer Therapy. Peters GJ (ed.) Humana Press, New York, pp253-288, 2006.
3. Hande KR and Garrow GC: Purine antimetabolites. In: Cancer Chemotherapy and Biotherapy: Principles and Practice. Chabner BA and Longo DL (eds.) Lippincott-Raven, New York, pp235-252, 1996.
4. Bonate PL, Arthaud L, Cantrell WR Jr, Stephenson K, Secrist JA III and Weitman S: Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 5: 855-863, 2006.
5. Pui CH, Jeha S and Kirkpatrick P: Clofarabine. Nat Rev Drug Discov 4: 369-370, 2005.
6. Faderl S, Gandhi V, Keating M, Jeha S, Plunkett W and Kantarjian H: The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog. Cancer 103: 1985-1995, 2005.
7. Xie C and Plunkett W: Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine in human lymphoblastoid cells. Cancer Res 55: 2847-2852, 1995.
8. Parker WB, Allan PW, Hassan AE, Secrist JA III, Sorscher EJ and Waud WR: Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 10: 23-29, 2003.
9. Xie KC and Plunkett W: Deoxynucleotide pool deletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine. Cancer Res 565: 3030-3037, 1996.
10. Genini D, Adachi, S, Chao Q, et al: Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96: 3537-3543, 2000.
11. Pessina A: Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci 75: 355-367, 2003.
12. Kummar S, Gutierrez M, Doroshow JH and Murgo AJ: Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 62: 15-26, 2006.
13. Masubuchi N, May RD and Atsumi R: A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay. Clin Cancer Res 10: 6722-6731, 2004.
14. Erickson-Miller CL, May RD, Tomaszewski J, Osborn B, Murphy MJ, Page JG and Parchment RE: Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol 39: 467-472, 1997.
15. Kurtzberg LS, Battle T, Rouleau C, et al: Bone marrow and tumor cell CFU and human tumor xenograft efficacy of non-camptothecin and camptothecin topoisomerase I inhibitors. Mol Cancer Ther 7: 3212-3222, 2008.
16. Beckwith M, Longo DL, O'Connell CD, Moratz CM and Urba WJ: Phorbol ester-induced cell cycle-specific growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst 82: 501-509, 1990.
17. Matsuoka Y, Moore GE, Yagi Y and Pressman D: Production of free light chains of immunoglobulin by a haematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 125: 1246-1250, 1967.
18. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23, 1979.
19. Fogh J (ed.): In: Human Tumor Cells In Vitro 43. Plenum Press, New York, pp115-159, 1975.
20. Belani R and Saven A: Cladribine in hairy cell leukemia. Hematol Oncol Clin North Am 20: 1109-1123, 2006.
21. Gidron A and Tallman MS: 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up. Leuk Lymphoma 47: 2301-2307, 2006.
22. Robak T: The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland. Ann Hematol 84: 63-70, 2005.
23. Robak T, Wierzbowska A and Robak E: Recent clinical trials of cladribine in hematological malignancies and autoimmune disorders. Rev Rec Clin Trials 1: 15-34, 2006.
24. Carson DA, Wasson DB, Kaye J, Ullman B, Martin DW Jr, Robins RK and Montgomery JA: Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignat human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 77: 6865-6969, 1980.
25. Carson DA, Wasson DB and Beutler E: Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci USA 81: 2232-2236, 1984.
26. Avramis VI, Wiersman S, Krailo MD, et al: Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a Phase I/II study in pediatric patients with relapsed leukemias. Clin Cancer Res 4: 45-52, 1998.
27. Robak T and Robak P: Current treatment options in prolymphocytic leukemia. Med Sci Monit 13: RA69-RA80, 2007.
28. +-activation of human concentrative nucleoside transporter 3. J Biol Chem 283: 24922-24934, 2008.
29. Zhang J, Visser F, King KM, Baldwin SA, Young JD and Cass CE: The role of nucleoside transporter in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 26: 85-110, 2007.
30. Tsang RY, Santos C, Ghosh S, et al: Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia. Mod Pathol 21: 1387-1393, 2008.
31. Parker WB, Shaddix SC, Chang CH, et al: Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 51: 2386-2394, 1991.
32. Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ and Cottam HB: Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc Natl Acad Sci USA 89: 2970-2974, 1992.
33. King KM, Damaraju VL, Vickers MF, et al: A comparison of the transportability, and its role in cytotoxicty, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol 69: 346-353, 2006.
34. Gradhand U and Kim RB: Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev 40: 317-354, 2008.
35. Ravna AW, Sylte I and Sager G: Molecular model of the outward facing state of the human P-glycoprotein (ABCB1) and comparison to a model of the human MRP5 (ABCC5). Theor Biol Med Mod 4: 33-46, 2007.
36. Sampath J, Adachi M, Hatse S, et al: Role of MRP4 and MRP5 in biology and chemotherapy. AAPS Pharm Sci 4: 1-9, 2002.
37. Wielinga PR, Reid G, Challa EE, et al: Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 62: 1321-1331, 2002.
38. Lotfi K, Mansson E, Spasokoukotskaja T, et al: Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analog of cladribine in human leukemic cells. Clin Cancer Res 5: 2438-2444, 1999.
39. Gandhi V. Kemena A, Keating MJ and Plunkett W: Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma 10: 49-56, 1993.
40. Gandhi V and Plunkett W: Clofarabine: mechanisms of action, pharmacology and clinical investigations. In: Deoxynucleoside Analogs in Cancer Therapy. Peters GJ (ed.) Humana Press, New York, pp153-171, 2006.
41. Takahashi T, Kanazawa J, Akinaga S, Tamaoki T and Okabe M: Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol 43: 233-240, 1999.
42. Kantarjian H, Gandhi V, Kozuch P, et al: Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21: 1167-1173, 2003.
43. Chiao N, Bumgardner A and Duvic M: Clofarabine-induced acral erythema during the treatment of patients with myelodysplasia and acute leukemia: report of two cases. Leuk Lymphoma 44: 1405-1407, 2003.
44. Peterson JK and Houghton PJ: Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40: 837-844, 2004.
45. Karp JE, Ricklis RM, Balakrishnan K, et al: A phase I clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 110: 1762-1769, 2007.
46. Faderl S, Gandhi V, O'Brien S, et al: Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemia. Blood 105: 940-947, 2005.
47. Faderl S, Ravandi F, Huang X, et al: A randomized study of clofarabine versus clofarabine plus low dose cytarabine as frontline therapy for patients age ≥60 years with acute myeloid leukemia and high risk myelodysplastic syndrome. Blood 112: 1638-1645, 2008.